UB Paderborn / Katalog / Suche / in CDI

1 – 18 von 18

Sortiert nach

Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

Journal of clinical oncology, 2009-11, Vol.27 (32), p.5363-5369

2009

Volltextzugriff (PDF)

Randomized, Open-Label, Phase III Study of a 28-Day Oral Regimen of Eniluracil Plus Fluorouracil Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Therapy in Patients With Metastatic/Advanced Colorectal Cancer

Journal of clinical oncology, 2002-03, Vol.20 (6), p.1519-1526

Schilsky, R. L.

2002

Volltextzugriff (PDF)

Multicenter Phase II Study of a 28-Day Regimen of Orally Administered Eniluracil and Fluorouracil in the Treatment of Patients With Anthracycline- and Taxane-Resistant Advanced Breast Cancer

Journal of clinical oncology, 2002-02, Vol.20 (4), p.987-993

Rivera, E.

2002

Volltextzugriff (PDF)

Multicenter Phase II Study to Evaluate a 28-Day Regimen of Oral Fluorouracil Plus Eniluracil in the Treatment of Patients With Previously Untreated Metastatic Colorectal Cancer

Journal of clinical oncology, 2000-08, Vol.18 (15), p.2894-2901

2000

Volltextzugriff (PDF)

Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study

Supportive care in cancer, 2012-07, Vol.20 (7), p.1471-1478

2012

Volltextzugriff (PDF)

Phase 2 trial results with the novel neurokinin‐1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

Cancer, 2009-12, Vol.115 (24), p.5807-5816

2009

Volltextzugriff (PDF)

Phase II Study to Evaluate the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antagonist Casopitant (GW679769) Administered with Ondansetron for the Prevention of Postoperative and Postdischarge Nausea and Vomiting in High-risk Patients

Anesthesiology (Philadelphia), 2010-07, Vol.113 (1), p.74-82

2010

Volltextzugriff (PDF)

Whole brain radiation therapy (WBRT) with or without oral topotecan (TPT) in patients (pts) with non-small cell lung cancer (NSCLC) with brain metastases: Final analysis of an open-label phase III study

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2031-2031

2013

Volltextzugriff (PDF)

Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis

The oncologist (Dayton, Ohio), 2005-10, Vol.10 (9), p.686-694

2005

Volltextzugriff (PDF)

Topotecan in the Treatment of Relapsed Small Cell Lung Cancer Patients with Poor Performance Status

The oncologist (Dayton, Ohio), 2004-01, Vol.9 (2), p.173-181

2004

Volltextzugriff (PDF)

Clinical development of eniluracil/fluorouracil : an oral treatment for patients with solid tumors: The Oral Fluorinated Pyrimidines

Investigational new drugs, 2000, Vol.18 (4), p.383-390

2000

Volltextzugriff (PDF)

Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors

Investigational new drugs, 2000-11, Vol.18 (4), p.383-390

2000

Volltextzugriff (PDF)

Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study

Archives of surgery (Chicago. 1960), 2011-02, Vol.146 (2), p.201

2011

Volltextzugriff (PDF)

Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer

Journal of clinical oncology, 2002-02, Vol.20 (4), p.987-993

2002

Volltextzugriff (PDF)

Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer

Journal of clinical oncology, 2002-03, Vol.20 (6), p.1519-1526

2002

Volltextzugriff (PDF)

A Phase I Trial of Weekly Paclitaxel Plus Prolonged Oral Eniluracil/5‐Fluorouracil in Patients with Refractory Malignancies

The oncologist (Dayton, Ohio), 2002-01, Vol.7 (5), p.444-450

2002

Volltextzugriff (PDF)

CARCINOGEN METABOLISM AND DNA DAMAGE IN THE RODENT PANCREAS

LEVIN, JEREMEY

1984

Volltextzugriff (PDF)

DNA damage in isolated hamster and rat pancreas cells by pancreatic carcinogens

Chemico-biological interactions, 1984, Vol.48 (1), p.59-67

1984

Volltextzugriff (PDF)

1 – 18 von 18

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(17)
Dissertationen
(1)

Sprache

Englisch
(18)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

Randomized, Open-Label, Phase III Study of a 28-Day Oral Regimen of Eniluracil Plus Fluorouracil Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Therapy in Patients With Metastatic/Advanced Colorectal Cancer

Multicenter Phase II Study of a 28-Day Regimen of Orally Administered Eniluracil and Fluorouracil in the Treatment of Patients With Anthracycline- and Taxane-Resistant Advanced Breast Cancer

Multicenter Phase II Study to Evaluate a 28-Day Regimen of Oral Fluorouracil Plus Eniluracil in the Treatment of Patients With Previously Untreated Metastatic Colorectal Cancer

Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study

Phase 2 trial results with the novel neurokinin‐1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

Phase II Study to Evaluate the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antagonist Casopitant (GW679769) Administered with Ondansetron for the Prevention of Postoperative and Postdischarge Nausea and Vomiting in High-risk Patients

Whole brain radiation therapy (WBRT) with or without oral topotecan (TPT) in patients (pts) with non-small cell lung cancer (NSCLC) with brain metastases: Final analysis of an open-label phase III study

Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis

Topotecan in the Treatment of Relapsed Small Cell Lung Cancer Patients with Poor Performance Status

Clinical development of eniluracil/fluorouracil : an oral treatment for patients with solid tumors: The Oral Fluorinated Pyrimidines

Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors

Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study

Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer

Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer

A Phase I Trial of Weekly Paclitaxel Plus Prolonged Oral Eniluracil/5‐Fluorouracil in Patients with Refractory Malignancies

CARCINOGEN METABOLISM AND DNA DAMAGE IN THE RODENT PANCREAS

DNA damage in isolated hamster and rat pancreas cells by pancreatic carcinogens

Suchergebnisse filtern